InvestorsHub Logo
Followers 13
Posts 865
Boards Moderated 0
Alias Born 02/17/2017

Re: DewDiligence post# 2548

Saturday, 02/25/2017 7:45:59 PM

Saturday, February 25, 2017 7:45:59 PM

Post# of 4876
Thanks for the information Dew, much appreciated. Interested to hear your take on the possibility of significantly reduced adverse effects with a new treatment option. If you set aside patient compliance and efficacy as roughly equal (oversimplification, of course), do you think a preference towards lack of potential hepatoxicity, immune function impairment, etc, might be enough to make a new treatment more commercially viable?

Obviously hypotheticals, but hey, I'm not trying to sell a company to anyone on this board. Just interested in different opinions and trains of thought. Appreciate the GILD folks here letting me crash the party for a few minutes.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GILD News